INCAGN02385, Retifanlimab (INCMGA00012), INCAGN02390
INCAGN 2385-203
Phase 2 small_molecule active
Quick answer
INCAGN02385, Retifanlimab (INCMGA00012), INCAGN02390 for In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN. is a Phase 2 program (small_molecule) at Incyte Biosciences Distribution B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Incyte Biosciences Distribution B.V.
- Indication
- In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active